chenai conf copy
TRANSCRIPT
Guidelines of extravasation, infection &pain
management in Oncology
Dr. O.P. Singh M.D.FICRO.
Prof & H.O.D
(Radiotherapy)
Gandhi Medical College Bhopal
, India
Dr. Gopa Ghosh M.D,
Associate prof (Radiotherapy)S.S. Medical
College Rewa ,India
Extravasation can be defined as
leakage of drug in to subcutaneous
tissue which leads to either irritation
or vescication.
Classification of Cytotoxic drugs
according to local site reaction
1.Irritan
ts
Inflamm
ation,irr
itation,
Pain
2.Inflam
mitants
Inflamma
tion/flare
3.Exfolia
nts
Shedding
/Exfoliati
on of
skin ,no
necrosis
4.Vescica
nts
Tissue
Ulceratio
n&necros
is
5.Neutrals do not cause any damage
Extravasation of a vescicant is a
medical emergency hence calls
for early detection &prompt
action to prevent functional loss
of limb involved.
Common Exfoliants &
Vescicants
Exfoliants
Liposomal
Daunorubicin
Liposomal
doxorubicin
Cisplatin
Mitoxantrone
Oxalaplatin
Vescicants
Doxorubicin
Daunorubicin
Epirubicin
Dactinomycin
Mitomycin C
Vincristine
Vinblastine
Paclitaxol
Probable risk factors for
Peripheral
Extravasation: Thin fragile veins
Site of cannulation
Peripheral neuropathy(Diabetes)
Excessive movements due to altered mental status,vomitting,coughing
SVC Syndrome
Elderly/ Paediatric
Obese
Prior chemotherapy
Cause of Central venous catheter
leakage
Backflow secondary to thrombosis in the catheter.
Needle dislodgement from the port
Damage of the catheter
Thrombocytopenia
Prevention of extravasation
Careful assesment of cannulation site
Cannulation over joints to be avoided
Patients at increased risk of extravasation should be
identified.
Vescicant drugs to be given before other drugs
Bolus doses are given via fast running infusion of
compatible fluid
Continuous observation of cannulation site for signs of
swelling ,pain inflammation, slowing of drip rate.
Opinion for placement of CVAD should be sought if
Peripheral access difficult.
Extravastion can also occur in central access often of
delayed onset .
Signs/Symptom's
Burning ,stinging ,pain at injection site
Swelling ,redness , blister.
Absence of free flow of infusion
Resistance on the plunger of the syringe in
case of bolus drug infusion
No blood return in the cannula.
Steps in management of
extravasation
Stop infusion ,disconnect tubing
Withdraw as much as drug possible via existing
cannula or CVAD
Mark skin area with indelible pen
Take photograph of the area
Open extravasation kit
Apply hot/cold pack as applicable for the concerned
drug.
Elevate the limb
Inform treating oncologist
Urgent assesment by oncologist regarding referral to
plastic surgeon for saline flush out of extravasated
area.
Follow up at regular intervals.
Contents of extravasation kit
Inj Hyaluronidase (1ampoule/1500iu)
Hydrocortisone 1%cream
S/w for injection
DMSO98%solution
Hot pack
Cold pack
Drugs vs. Warm/Cold pack
Vinca alkoids, Paclitax, Oxaloplatin
Hyaluronidase+ Warm pack
Anthracyclins,Mitoxantrone,Mitomycin,Dacti
nomycinColdpack+DMSO+1%hudrocortis
one
cream
Carboplat,Cisplat,Etoposide,5FU,Irrinotican,
Mtx- Coldpack & Hydrocortisone cream
Regime of Warm & Cold pack
Warm
1amp Hyaluronidase
s.c. inj
Warm pack to aid in
absorption
Leave warm pack in
situ for 2-4hrs
Cold
cold pack +
Hydrocortison ecream
3days
Hydrocortisone
1%cream tds
OR
Cold pack +
hydrocortisone cream
+ DMSO
DMSO application regimeThin layer 98% DMSO1%hydrocortisoneCold
compress
Rpt every2hr/24hrs
DMSO 6hrly7days
Alt toDMSO1% Hydrocortisone 6 hrly7days
Cancer pain a matter of
concern 60-80% of terminal cancer patients have severe pain
Moderate pain exists in earlier course of the disease
also.
QOL of such patients are significantly impaired due to
pain.
Chronic pain expressed in vague terms (stiffness
,anxiety ,insomnia), actual prevalance underestimated
85% cases can be pain free with modern drugs &
techniques.
Etiology1. Direct infiltration to mucosa, soft tissues ,nerve
&bone.
2.Treatment related (Sx/RT/CT) accounts for 20%
pain cases.
Pain produced- stimulation of peripheral pain
receptors.(nociceptive)
Neurogenic/Neuropathic-( involvement of
afferent nerves or nerve pathways.)
Broad Principles of drug treatment
Simplest dosage and least invasive route to be used
first
Analgesics to be given preferably around the clock basis
than as need basis for more effective pain control.
Opioid dose till ultimate pain relief or unacceptable
side effects.
NAIDS &adjuvant analgesics with ceiling effect, dose
till upper limit of recommended dose
Switching of analgesics when required
Primary cause of pain i.e. tumour to be treated with
palliative appropriate modality (RT/CT/Sx )
Adjuvants( Antidepressants, Anticonvulsants
biphosphonates, steroids, etc)used when required to
enhance efficacy of analgesia, treat concurrent
symptoms ,independent analgesic effect for specific type
of pain .
Reasons for Comprehensive pain
assesment
1.Pain expression influenced by factors:
Cognitive status
Extreme of age
Psychological reasons(fear of morphine related side
effects, progressive disease)
Religious beliefs
Communication barrier
2,Asses pain components: Bony
.Neuropathic
.Behavioral
.Somatic
3.Asses Comorbid conditions
(Renal,hepatic,Coagulopathy,GI,Respiratory)
Some Pain assesment scale1.Numeric scale(0-10) based on patients own pain report
2. Rupee scale.
Children : Face scale Happy to sad
2.Comprehensive pain evaluation:
By PQRST factor(Provocative, quality , referred/regional
severity, temporal factors like onset ,duration ,frequency etc.
WHO designed simple, effective ,well validated
adjustment of pain therapy which results in pain relief in
90% cases, known as WHO pain ladder
Some common analgesics proposed for use:
NSAIDs-Aspirin, Ibuprofen , Naproxen , Piroxicam
, Celecoxib
Weak Opioid-Codeine, dextropropoxyphine, Tramadol,
Strong opioid-Morphine, buprenorphine, transdermal
Fentanyl
WHO LADDER OF
PAIN(cont.)
1-3 ,NSAID+/-
Adjuvant
4-6,WEAKOPIOID,+/-NONOPIOID+/-ADJUVANT
7-10,STRONG
OPIOID=/-NONOPIOID+/-ADJUVANT
Pharmacologic Management Drug therapy remains the cornerstone of cancer pain
management reasons being:
safe
Inexpensive
Works fast
Better compliance
3 major classes of drugs are:
NSAIDS & Acetaminophen
Opioid analgesics
Adjuvant analgesic agents
Non Pharmacologic
Techniques Anesthetic - Local anesthetic
-Nerve block
Neurosurgical techniques-Nerve ablation
-Nerve division
- Implant of device for
electrical stimulation
Physical methods-Heat ,cold, acupuncture , electrical
stimuli
.Cognitive techniques
1-15% cases requires invasive technique.
Morphine dose/side effects Inexpensive opioid given commonly by oral route
Starting dose 10mg 4hrly,TDD usually 20-40mg , by
50% subsequently
Parenteral dose 1/3rd of OD
Breakthrough pain(10-15%) of daily dose.
No max. dose.
Extended release preparations when frequent dosing
required
Side effects requiring dose
modification ,adjuvants ,Switching
,alternate routes
Constipation
Sedation
Myoclonus
Opioid toxicity syndrome(OTS)-RF ,dehydration, severe
myoclonus
Withdrawal symptoms
Infection in oncology
Reason for significant morbidity & mortality
Oncologist should have thorough understanding of risk
factors &common etiologic microbes
Prompt work up & therapy are key to successful
management
Causes
immunity-disease itself
-treatment induced neutropenia
.Protein malnutrition
Altered cellular/Humoral immunity
.Nosocomial
Post operative
.Secondary to obstruction & necrosis
.Exposure to community acquired pathogens(HSV,CMV)
.Reactivation of latent infections
Common Symptoms
Fever
Tachypnea
Tachycardia
Hypotension
Hypothermia
Organ specific
Organ failure
Routinely diagnosed by laboratory, microbial ,radiological tests
Guidelines for treatment Prompt initiation of broad spectrum antimicrobial empiric
monotherapy in suspected infections without waiting for
lab reports
Directed therapy against specific pathogens as per
microbial culture report.
In case β-lactam allergy fluoroquinolone based therapy
given.
Diagnosis of febrile neutropenia should be done in
fever cases with ANC< 500/μl ,WBC <1000/μl.
Documented bacteremia treated at least for 14 days.
Common pathogens S.aureus
Enterococcus
Pseudomonas
C.difficle
Klebsiella
Proteus
E.coli
Candida
Aspergillus
CMV
Common Antimicrobials 3rd /4th gen cephalosporins
Carbapenems(Imepenem/Merpenem)
Piperacillin-tazobactam
Amoxycillin-clavulanate
Fluoroquinolones
Aztreonam
Fluconazole
Voriconazole
Amphotericin-B
Acyclovir
Thank you